Career Development Fellow
I am interested in imaging as a valuable tool for the diagnosis, new potential target identification and response to treatment detection in pathologies where a non-invasive approach is essential, as in the case of brain diseases. My previous research was focused on characterizing the metabolic response/resistance of preclinical brain tumours (and other types of cancer) to chemotherapeutic agents and targeted therapies using diverse imaging techniques (DCE-MRI, DWI, MRS, MRSI).
Nowadays, Parkinson’s disease is the second most common neurodegenerative disorder worldwide and a biomarker-based multimodal imaging approach could be very valuable for early diagnosis and drug target identification and validation. My aim now is to apply my imaging skills to the development of MRI and molecular imaging protocols (mainly based on [18F]-fluorodopa (FDOPA) uptake, imaged using positron emission tomography (PET)) to study the progressive neurodegenerative phenotype in previously established BAC-LRKK2 transgenic models that mimic the human disease, and compare these findings with clinical data.